Skip to main content

Table 4 Summary cost-effectiveness findings in patients with GI-NET

From: Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

 

177Lu-Dotatate

BSC (Octreotide LAR)

Δ

Total costs, GBP

84,990

49,289

35,701

Quality-adjusted life expectancy, QALYs

3.25

1.92

1.33

ICER, GBP per QALY gained

26,830

  1. BSC best supportive care, GI-NET gastrointestinal neuroendocrine tumor, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year